Profusa, Inc. (NASDAQ:PFSA) Shares Shorted: Short Interest Up 409.3% in September

Posted by Brenda Bartman on Oct 10th, 2026

Profusa, Inc. (NASDAQ:PFSA – Get Free Report) saw a significant growth in short interest in the month of September. As of September 30th, there was short interest totaling 160,653 shares, a growth of 409.3% from the September 15th total of 31,545 shares. Currently, 31.2% of the shares of the company are sold short. Based on an average daily volume of 9,017,408 shares, the short-interest ratio is currently 0.0 days.

Insider Activity

In other news, major shareholder Financial Lp Hrt sold 10,602 shares of the firm’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $3.56, for a total transaction of $37,743.12. Following the sale, the insider directly owned 18,549 shares in the company, valued at $66,034.44. This trade represents a 36.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last ninety days, insiders have acquired 4,308 shares of company stock valued at $16,594. Insiders own 15.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on PFSA shares. Wall Street Zen raised shares of Profusa to a “sell” rating in a research note on Saturday, August 22nd. Weiss Ratings upgraded shares of Profusa from a “sell (e)” rating to a “sell (e+)” rating in a report on Thursday, August 27th. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company currently has an average rating of “Sell”.

Read Our Latest Report on Profusa

Profusa Stock Down 4.7%

PFSA opened at $1.42 on Friday. The business has a 50 day moving average price of $3.66 and a two-hundred day moving average price of $26.02. Profusa has a 52 week low of $1.40 and a 52 week high of $3,000.00. The company has a market cap of $866,200.00, a PE ratio of -0.00 and a beta of 0.53.

Profusa (NASDAQ:PFSA – Get Free Report) last issued its earnings results on Wednesday, August 19th. The company reported ($151.80) EPS for the quarter.

Profusa Company Profile

(Get Free Report)

Profusa, Inc is a biotechnology company developing implantable biosensor technology designed to continuously monitor body chemistry. Its sensors are engineered to integrate with tissue and detect selected biological signals, with the goal of providing real-time health data through an external reader or connected digital device.

The company’s technology platform has been studied for applications including monitoring oxygen and other biomarkers that may assist with disease management, clinical research, and personalized healthcare.